Marina Udier, Nouscom CEO

Swiss can­cer vac­cine biotech Nous­com rais­es $72M Se­ries C for PhII tri­als

Basel-based biotech Nous­com has raised €67.5 mil­lion ($72.2 mil­lion) to bankroll its can­cer vac­cines as the eight-year-old com­pa­ny looks to cap­i­tal­ize on mo­men­tum in the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.